Equities

Ultimovacs ASA

Ultimovacs ASA

Actions
  • Price (EUR)0.1434
  • Today's Change0.005 / 3.61%
  • Shares traded1.00k
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes, as of Sep 20 2024 07:12 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of NOK
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments270430579
Total Receivables, Net1.101.281.14
Total Inventory------
Prepaid expenses1.462.920.88
Other current assets, total0.001.080.76
Total current assets272436582
Property, plant & equipment, net3.685.662.16
Goodwill, net121111
Intangibles, net625860
Long term investments------
Note receivable - long term------
Other long term assets0.00----
Total assets349510656
LIABILITIES
Accounts payable117.6623
Accrued expenses121810
Notes payable/short-term debt000
Current portion long-term debt/capital leases1.831.771.63
Other current liabilities, total311916
Total current liabilities564651
Total long term debt1.893.710.46
Total debt3.715.482.09
Deferred income tax121111
Minority interest------
Other liabilities, total--0.000
Total liabilities706062
SHAREHOLDERS EQUITY
Common stock3.443.443.42
Additional paid-in capital1,0771,0761,071
Retained earnings (accumulated deficit)(861)(672)(504)
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total614223
Total equity279449593
Total liabilities & shareholders' equity349510656
Total common shares outstanding343434
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.